drugset / Trial / NCT07527325
Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma
Phase 2
Not yet recruiting
35 enrolled
University of California, Irvine
UC Cancer Consortium · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a phase II, open label clinical trial determining efficacy of Fianlimab in combination with Cemiplimab in subjects with Melanoma. These are subjects who will have surgery to remove their cancer.
Timeline
- Start
- 2026-07-01
- Primary completion
- 2029-02-01
- Completion
- 2030-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | 350 mg | Intravenous |
| Subject | Fianlimab | Monoclonal antibody | 1600 mg | Intravenous |